06/12/2018 15:14:14

Beyond Celiac partners with imaware™ to expand use of at-home celiac disease testing for faster medical diagnosis

Philadelphia, PA, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Beyond Celiac today announced their newest partner, imaware™.  imaware™ is a unique at-home celiac disease screening and monitoring test that is highly accurate and provides actionable results for patients. Beyond Celiac is partnering with imaware™ to support the ambitious goal of dramatically reducing the number of individuals dealing with undiagnosed celiac disease by helping them more quickly take the steps needed for diagnosis.

“Celiac disease has long been plagued by low diagnosis rates. It is estimated that less than 20 percent of patients who have the condition know it,” noted Alice Bast, Beyond Celiac CEO. “We hear from our community that their doctors do not want to test them despite symptoms. The average delay in diagnosis is 6 to 10 years. It took me eight years to get diagnosed,” she added.

A study published recently in the United European Gastroenterology Journal concluded that patients whose diagnosis had been delayed for three years reported being sick more often, going to the doctor more frequently and using more drugs for indigestion and depression than those who were diagnosed more quickly.

“We believe that the imaware™ at-home celiac disease test will help reduce the number of undiagnosed people with celiac disease,” said Jani Tuomi, Chief Product Officer for imaware™. “An easy to use test, with easy to read results that are reviewed by a doctor, will dramatically reduce time to diagnosis. With a partner like Beyond Celiac, we will be able to better engage with the patient community to educate, screen, and ultimately help patients engage their doctors sooner for diagnosis.”

The imaware™ test measures the same antibodies to gluten as the tests that doctors use in their offices as the first step to diagnose celiac disease – anti-tissue transglutaminase (tTG) and deaminated gliadin peptide (DGP) tests. In the United States, definitive diagnosis of celiac disease requires a biopsy that shows intestinal damage in addition to the blood test.

Sold online only, the imaware™ test requires a finger prick and collection of a small amount of blood in a vial. Consumers then mail their sample back and receive their confidential test results via a secure portal in about a week. For results to be accurate, consumers need to be on a normal gluten-containing diet. The imaware™ at-home test for celiac disease is available at imaware.health for $165.00. Beyond Celiac will receive a portion of sales to support their ongoing initiatives to drive diagnosis, advance research and accelerate the discovery of new treatments and a cure. 

XXX

About Celiac Disease

Celiac disease is a serious, genetic, autoimmune disorder that affects an estimated 1 in 100 Americans, the vast majority of whom are still undiagnosed. The disease causes debilitating symptoms, and if left untreated, can lead to serious long-term health problems including infertility and some types of cancer.

About Beyond Celiac:

A 501(c)(3) non-profit organization, Beyond Celiac envisions a world in which people with celiac disease can live healthy lives free from social stigma and fear of gluten exposure – A world Beyond Celiac.

Attachment

Claire Baker

Beyond Celiac

215-325-1306 ext. 111

cbaker@beyondceliac.org

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
24 May
OMXC25
Fattigdom i DK?   https://www.dr.dk/nyheder/politik/folketingsvalg/se-kort-flest-boern-ramt-af-relat..
26
21 May
VELO
Så er der lidt at læse på. . Se bla.. Purpose: Tacrolimus extended release (TacER) (Envarsus XR®) ha..
21
23 May
VELO
Har modtaget data, som viser en stigning i receptal på 20% siden Januar 2019.  
19
18 May
VWS
Ditlev.. Havde store ambitioner, og store armbevægelser .. Ikke alt gik godt.. Men finanskrisen kan..
18
20 May
PNDORA
Paa trods af et godkendt Q1 regnskab, er aktien faldet som en sten. Markedet er ligeglad med Pandora..
17
22 May
VWS
Vestas secures 44 MW order for V120-2.2 MW turbines with tall tower solution News release from Ves..
16
20 May
DANSKE
Hører på Radio247 at Jyske Bank er indblandet i momssvindel via et par kunder. Penge ud og ind på en..
15
18 May
AMBU-B
Cook Medical er en førende amerikansk medicovirksomhed med en omsætning på ca. 2 mia. usd og aktivit..
14
18 May
VELO
Jeg er meget uenig med dig Munch. For mig er toplinjen klart mest interessant lige nu, for det er de..
14
23 May
VELO
Kære Nikw. Sagen er kort, at data af konkurence hensyn ikke sendes til højre eller venstre. Man kan ..
13

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Gopher Protocol Issues Statement Pertaining to Affiliate Status of Third Party Institutional Investor
2
Gopher Protocol Issues Statement About Recent Stock Trading Activity – Notice to the Public to Rely on Information only Provided by the Company
3
CTSH INVESTIGATION REMINDER: Hagens Berman Reminds Cognizant Technology (CTSH) Investors of Ongoing Investigation, Encourages Investors and Persons With Knowledge to Contact the Firm
4
Bragar Eagel & Squire, P.C. is Investigating AZZ Inc. (NYSE: AZZ) on Behalf of AZZ Stockholders and Encourages AZZ Investors to Contact the Firm
5
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against PriceSmart, Inc. (PSMT)

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
25 May 2019 20:48:30
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190514.2 - EUROWEB2 - 2019-05-25 21:48:30 - 2019-05-25 20:48:30 - 1000 - Website: OKAY